A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF LORLATINIB (PF-06463922) MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009380/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to
crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC
patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to
overall survival in the same population
提供机构：
Vivli
创建时间：
2023-10-19
